Editorial
Predicting the future of urodynamics
Translational Andrology and Urology
2012;
1
(2)
:76-77
.
(30 June 2012)
Review Article
TGF-β mediated DNA methylation in prostate cancer
Translational Andrology and Urology
2012;
1
(2)
:78-88
.
(30 June 2012)
Systemic implications of urinary stone disease
Translational Andrology and Urology
2012;
1
(2)
:89-96
.
(30 June 2012)
Mast cells, estrogens, and cryptorchidism: A histological based review
Translational Andrology and Urology
2012;
1
(2)
:97-102
.
(30 June 2012)
Phalloplasty for the genetic male
Translational Andrology and Urology
2012;
1
(2)
:103-108
.
(30 June 2012)
Expert Opinions on Challenging Cases
Commentary on high flow, non-ischemic, priapism
Translational Andrology and Urology
2012;
1
(2)
:109-112
.
(30 June 2012)
Research Highlight
Denosumab: Delay of bone metastasis in men with nonmetastatic
Translational Andrology and Urology
2012;
1
(2)
:113-114
.
(30 June 2012)
Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
Translational Andrology and Urology
2012;
1
(2)
:115-117
.
(30 June 2012)
Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
Translational Andrology and Urology
2012;
1
(2)
:118-119
.
(30 June 2012)
Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
Translational Andrology and Urology
2012;
1
(2)
:120-122
.
(30 June 2012)
Milestones for development of tivozanib for kidney cancer therapy
Translational Andrology and Urology
2012;
1
(2)
:123-125
.
(30 June 2012)
Perspective
Erectile dysfunction: Doctors’ perspectives on patients’ concerns
Translational Andrology and Urology
2012;
1
(2)
:126-128
.
(30 June 2012)
Meeting Report
Translational andrology and urology research: Where is it heading? --Report of the 5th Greatwall Translational Andro-Urology Forum (GTAUF2012)
Translational Andrology and Urology
2012;
1
(2)
:129-140
.
(30 June 2012)
Disclosure:
The series “Meeting Report” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding
